You are here

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Research Site
Shreveport, Louisiana, United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-90 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patient must be ≥18 and ≤90 years of age

- Female patients can participate if they are surgically sterile or completed menopause
or females capable of having children and agree not to attempt pregnancy while
receiving IV study therapy and for a period of 7 days after

- Patient has a ceftazidime-resistant Gram negative pathogen that was isolated from an
appropriate culture within 5 days prior to study entry (ie, within 5 days prior to
Screening; the study-qualifying culture), which was determined to be the causative
agent of the entry infection

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patient has an APACHE II score >30 (cIAI patients only)

- Patient has an infection due to Gram negative pathogen that is unlikely to respond to
CAZ-AVI treatment (eg, Acinetobacter spp., Stenotrophomonas spp.)

- Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant
Patient is immunocompromised

- Patient has a rapidly progressive or terminal illness with a high risk of mortality
due to any cause, including acute hepatic failure, respiratory failure or severe
septic shock such that they are unlikely to survive the 4- to 5-week study period.

NCT01644643
Pfizer
Completed
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
To Evaluate the Effects of Ceftazidime-Avibactam and Best Available Therapy in patients with complicated urinary tract infections and complicated intra-abdominal infections.
An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Complicated Urinary Tract Infection
  • Complicated Intra-abdominal Infection
  • Drug: Ceftazidime - Avibactam ( CAZ-AVI)
    Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
  • Drug: Best Available Therapy
    Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
  • Drug: Metronidazole
    Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
    Other Name: Flagyl
  • Experimental: Ceftazidime - Avibactam ( CAZ-AVI)
    IV treatment
    Interventions:
    • Drug: Ceftazidime - Avibactam ( CAZ-AVI)
    • Drug: Metronidazole
  • Active Comparator: Best Available Therapy
    IV treatment
    Intervention: Drug: Best Available Therapy


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
345
September 2014
September 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient must be ?18 and ?90 years of age
  • Female patients can participate if they are surgically sterile or completed menopause or females capable of having children and agree not to attempt pregnancy while receiving IV study therapy and for a period of 7 days after
  • Patient has a ceftazidime-resistant Gram negative pathogen that was isolated from an appropriate culture within 5 days prior to study entry (ie, within 5 days prior to Screening; the study-qualifying culture), which was determined to be the causative agent of the entry infection

Exclusion Criteria:

  • Patient has an APACHE II score >30 (cIAI patients only)
  • Patient has an infection due to Gram negative pathogen that is unlikely to respond to CAZ-AVI treatment (eg, Acinetobacter spp., Stenotrophomonas spp.)
  • Patient is receiving hemodialysis or peritoneal dialysis or had a renal transplant Patient is immunocompromised
  • Patient has a rapidly progressive or terminal illness with a high risk of mortality due to any cause, including acute hepatic failure, respiratory failure or severe septic shock such that they are unlikely to survive the 4- to 5-week study period.
Sexes Eligible for Study: All
18 Years to 90 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Bulgaria,   Croatia,   Czechia,   France,   Israel,   Korea, Republic of,   Mexico,   Peru,   Philippines,   Poland,   Romania,   Russian Federation,   South Africa,   Spain,   Turkey,   Ukraine,   United States
Australia,   Belgium,   Brazil,   Chile,   China,   Czech Republic,   Denmark,   Finland,   Germany,   Greece,   Hungary,   India,   Italy,   Japan,   Puerto Rico,   Taiwan,   United Kingdom
 
NCT01644643
D4280C00006
2012-000726-21
Not Provided
Not Provided
Not Provided
Pfizer
Pfizer
Forest Laboratories
Study Director: Paul Newell, MBBS, MRCP AstraZeneca
Pfizer
August 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now